Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E

Inclusion Criteria: * Age 50 and above * Diagnosis of exudative age-related macular degeneration (subfoveal CNV) as shown on optical coherence tomography (OCT) - presence of intraretinal fluid, subretinal fluid or subretinal hyperreflective material and/or FFA (leakage classified as subfoveal or as juxtafoveal or extrafoveal) * Actively treated with aflibercept and given 3 monthly loading doses followed by treat and extend * Maximal interval period is less than or equal to 8 weekly injections * Patients must understand and sign the ethics board approved consent form Exclusion Criteria: * Ocular criteria: * Co-existing retinal and/or macular disease (DME, RVO, high myopia of 8 diopters or more, retinal detachment, macular hole stage 2 or above, significant vitreomacular traction or epiretinal membrane, etc.) * Co-existing ocular disease (glaucoma, uveitis etc.) * History of uveitis or intraocular inflammation, scleritis, or episcleritis * History of corneal transplant, pars planar vitrectomy or aphakia * History of therapeutic radiation to the region of the study eye * Media opacity obstructing investigation or assessment (cataract, corneal scar, vitreous hemorrhage) * Treat and extend period beyond 8 weeks * Any intravitreal injection of steroid within 3 months before randomization * Systemic criteria: * Poorly controlled systemic disease including hypertension and diabetes * Any acute coronary event or stroke within 6 months before randomization * Malignancy within 5 years * Systemic anti-VEGF treatment * Allergy or sensitivity to investigational product, including fluoresceine dye, anesthetics, aflibercept or brolucizumab